Exdensur (depemokimab-ulaa) is a medicine that treats what

Exdensur (depemokimab-ulaa) is a long-acting interleukin-5 antagonist primarily indicated for the treatment of severe asthma with an eosinophilic phenotype, especially suitable for adults and children aged 12 years and older. This medication is used as an add-on maintenance treatment and is designed to help control the symptoms of severe asthma. It should be noted that Exdensur is not suitable for the relief of acute bronchospasm or status asthmaticus, and special attention should be paid to this point when using it.

Asthma is a common chronic respiratory disease whose symptoms include difficulty breathing, coughing, chest tightness and wheezing, which seriously affects the patient's quality of life. Severe asthma is generally defined as requiring the use of moderate to high doses of inhaled corticosteroids to control asthma symptoms and often requires additional treatment, such as systemic corticosteroids or biologics, to prevent asthma exacerbations. The complexity of this disease makes management particularly difficult, especially in those patients characterized by an eosinophilic phenotype.

Eosinophilic asthma is a subtype characterized by abnormally elevated levels of eosinophils (a specific type of white blood cell) in the airways and/or blood. By antagonizing interleukin-5 (IL-5), Exdensur effectively reduces the production, activation and survival of eosinophils in the body, thereby alleviating the patient's symptoms to a certain extent. Its active ingredient, depemokimab-ulaa, is an ultra-long-acting IL-5 antagonist that helps control inflammatory responses by blocking the binding of IL-5 to eosinophil receptors.

In terms of administration,Exdensur is administered by subcutaneous injection every six months by professional medical personnel. The injection site can be the upper arm, thigh or abdomen. This method of administration not only facilitates patient use, but also improves treatment compliance.

It is worth mentioning thatDepemokimab is also being studied as an additional maintenance treatment option for adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP), showing its potential application value in a variety of respiratory diseases.

Reference materials:https://fanyi.sogou.com/text?keyword=&transfrom=auto&transto=zh-CHS&model=general